Netherton Syndrome Market Insights report from DelveInsight provides a thorough understanding of the Netherton Syndrome Market size by treatment, epidemiology, emerging therapies, market share of the various therapies, and the current and forecasted Netherton Syndrome Market size from 2019 to 2032 divided into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan) regions.
Netherton Syndrome Overview
Netherton syndrome (NS) is a rare autosomal recessive syndromic ichthyosis caused by mutations of the SPINK5 gene, which encodes the lymphoepithelial Kazal-type-related inhibitor (LEKTI) protein. The exact incidence of NS is unknown, partly because it is difficult to diagnose. With around 150 cases reported in the scientific literature, it is estimated that approximately 1/200,000 people worldwide have NS.
Download Sample Report- https://www.delveinsight.com/sample-request/netherton-syndrome-market
Regions covered in the report
Key highlights of the Netherton Syndrome Market Report
Netherton Syndrome Epidemiology Insights
The incidence and prevalence of NS have been estimated to be 1/200,000 births and 1–9/million, respectively; similar numbers are published in most of the literature available worldwide. Moreover, it has been reported that that NS could account for up to 18% of congenital erythroderma.
Netherton Syndrome Epidemiology Segmentation in the 7MM
Do you want to know more information related to report? If yes, visit here- https://www.delveinsight.com/sample-request/netherton-syndrome-market
Netherton Syndrome Market Insights
There is an urgent need for a targeted, effective and well-tolerated therapy. Kallikrein inhibitors represent a new potential therapy for NS. Kallikrein inhibition is typically absent in NS and thus, the inhibitor properties of this treatment may prevent or minimize the inflammatory cutaneous features that are generally present. One of the emerging molecule, LM-030 (previously known as BPR277), now licensed to LifeMax, has been granted Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation by the FDA for topical treatment of NS. It is an inhibitor of kallikrein-related peptidase 7 (KLK7) and epidermal elastase 2 (ELA2), targets the underlying cause of NS, and is well-positioned to become the first approved treatment for this debilitating and potentially life-threatening disease.
Netherton Syndrome Therapeutics Market
There is no curative or specific therapy targeting NS pathophysiology and NS treatment is mostly palliative. The therapeutic strategies for NS can be classified into two broad categories:
Netherton Syndrome Market Size
Netherton Syndrome market size in the 7MM was USD XXXX million in 2021. The market size shall increase during the forecast period (2019–2032), owing to the launch of upcoming therapies.
Netherton Syndrome Emerging Therapy Assessment
There is no approved treatment for Netherton Syndrome. Current approaches are all limited to symptom relief or supportive care with marginal efficacy and undesirable side effects. There is an urgent need for a targeted, effective and well-tolerated therapy.
Netherton Syndrome Market Dynamics
Netherton Syndrome market dynamics is anticipated to change in the coming years owing to the improvement in the research and development undertaking. There are several key players involved in developing the therapies for Netherton Syndrome like LifeMax Laboratories, AnaptysBio and Janssen Biotech. The launch of emerging therapies is expected during the forecast period of 2022-2032.
Request Sample Report- https://www.delveinsight.com/sample-request/netherton-syndrome-market
Table of Content
1. Key Insights
2. Netherton Syndrome Executive Summary
3. Competitive Intelligence Analysis for Netherton Syndrome
4. Netherton Syndrome: Market Overview at a Glance
5. Netherton Syndrome: Disease Background and Overview
6. Netherton Syndrome Patient Journey
7. Netherton Syndrome Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Netherton Syndrome Unmet Needs
10. Key Endpoints of Netherton Syndrome Treatment
11. Netherton Syndrome Marketed Products
12. Netherton Syndrome Emerging Therapies
13. Netherton Syndrome: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Netherton Syndrome Market Outlook
16. Access and Reimbursement Overview of Netherton Syndrome
17. KOL Views
18. Netherton Syndrome Market Drivers
19. Netherton Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Netherton Syndrome Market Report Scope
Why should you buy this report?
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/